Stay updated on ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial
Sign up to get notified when there's something new on the ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial page.

Latest updates to the ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial page
- CheckyesterdayChange DetectedThe update appears to reflect only minor UI/layout changes with no alterations to core study content (title, BRCA mutation, interventions, outcomes, or eligibility). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange Detected- Added a government funding lapse notice and operating-status guidance, plus a version bump to v3.2.0. - Removed the old version reference v3.1.0.SummaryDifference2%

- Check30 days agoChange DetectedPage version updated to v3.1.0; removal of the term 'Ovarian cancer'.SummaryDifference0.1%

- Check44 days agoChange DetectedUpdated from v3.0.1 to v3.0.2 and removed the 'Back to Top' element. No other core content or key information appears to have changed.SummaryDifference0.1%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check59 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations related to ovarian cancer treatment, as well as the inclusion of a new study on rucaparib for relapsed ovarian cancer. Several previous entries have been removed, particularly those related to locations and cancer types.SummaryDifference8%

Stay in the know with updates to ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial page.